This 52-week research study is evaluating an oral investigational drug (KarXT) that is given to
participants experiencing negative symptoms of schizophrenia. The study aims to assess the long term safety and tolerability of the KarXT treatment in subjects who have been diagnosed with Schizophrenia.
Key Eligibility Criteria:
To pre-qualify for this study, an individual must:
- Be 18 to 65 years of age
- Subject must have a primary diagnosis of schizophrenia.
- Currently taking antipsychotic medication (taking same oral antipsychotic medication for at least 8 weeks prior screening, and taking the same dose at least 4 weeks prior to screening)
- Subject willing to discontinue all antipsychotics to initiate the KarXT treatment.
- Meet additional study criteria
Contact us or fill out the form below so we can reach out to you and move forward with pre-screening questions to assess your overall eligibility.